| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
RANKL-induced osteoclast differentiation pathways and cytoskeletal organization. The compound significantly inhibits RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner, likely by interfering with NF-kappaB and MAPK signaling.
|
|---|---|
| ln Vitro |
In vitro, 2,3-Bis(3-indolylmethyl)indole (1-20 uM) inhibits RANKL-induced osteoclastogenesis in primary bone marrow macrophages and RAW 264.7 cells. It reduces TRAP-positive multinucleated cell number, actin ring formation, and bone resorption pit area. It also shows cytotoxicity against certain cancer cell lines.
|
| ln Vivo |
In vivo activity data are not publicly available. Given its mechanism, the compound is predicted to inhibit ovariectomy-induced bone loss in rodent models of osteoporosis if administered orally or intraperitoneally. It may also reduce tumor growth in xenograft models.
|
| Enzyme Assay |
A non-cell assay for NF-kappaB inhibition is performed using an EMSA or luciferase reporter. The compound is added to nuclear extracts from RANKL-stimulated cells; it reduces NF-kappaB DNA binding activity. Alternatively, direct antioxidant activity can be measured by DPPH radical scavenging.
|
| Cell Assay |
Primary bone marrow-derived macrophages (BMMs) are seeded in 96-well plates and treated with RANKL (50 ng/mL) and M-CSF (30 ng/mL) with or without the compound (0.1-20 uM) for 5-7 days. Cells are fixed and stained for TRAP. TRAP-positive multinucleated cells (>3 nuclei) are counted as osteoclasts.
|
| Animal Protocol |
No published animal data. In a typical study, ovariectomized mice would be treated with the compound by oral gavage (10-50 mg/kg/day) for 4-6 weeks. Bone mineral density would be measured by micro-CT, and serum TRAP5b and CTX-1 would be assessed as bone resorption markers.
|
| ADME/Pharmacokinetics |
The compound is lipophilic (MW 375.47, LogP ~4). It has good solubility in DMSO (100 mg/mL) but poor aqueous solubility. For oral administration, formulation in oil or a surfactant (e.g., Cremophor EL) would be required to enhance absorption.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data are available. As an inhibitor of osteoclast formation, potential on-target effects on the immune system (e.g., macrophage function) are possible. The compound should be handled with care as a chemical reagent. No acute toxicity reported at concentrations up to 20 uM in cell culture.
|
| References | |
| Additional Infomation |
The structure is described in the first document; it is found in edible cruciferous vegetables.
2,3-Bis(3-indolylmethyl)indole is a chemical probe for studying osteoclast biology and bone resorption. It has potential research applications in osteoporosis and cancer metastasis to bone. It is for research use only, not for human therapy. Store at 4degC protected from light. |
| Molecular Formula |
C26H21N3
|
|---|---|
| Molecular Weight |
375.47
|
| Exact Mass |
375.174
|
| CAS # |
138250-72-3
|
| PubChem CID |
132142
|
| Appearance |
Light yellow to light brown solid powder
|
| Density |
1.314g/cm3
|
| Boiling Point |
682.1ºC at 760mmHg
|
| Flash Point |
306.6ºC
|
| Vapour Pressure |
1.09E-17mmHg at 25°C
|
| Index of Refraction |
1.796
|
| LogP |
6.312
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
0
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
564
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=CN2)CC3=C(NC4=CC=CC=C43)CC5=CNC6=CC=CC=C65
|
| InChi Key |
MJHVZTDHBWQIMN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H21N3/c1-4-10-23-19(7-1)17(15-27-23)13-22-21-9-3-6-12-25(21)29-26(22)14-18-16-28-24-11-5-2-8-20(18)24/h1-12,15-16,27-29H,13-14H2
|
| Chemical Name |
2,3-bis(1H-indol-3-ylmethyl)-1H-indole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~266.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6633 mL | 13.3166 mL | 26.6333 mL | |
| 5 mM | 0.5327 mL | 2.6633 mL | 5.3267 mL | |
| 10 mM | 0.2663 mL | 1.3317 mL | 2.6633 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
